Gideon M. Hirschfield
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 340 publications
Cholestatic Liver Disease Across the Life Span: A Primer for Clinicians.
Journal: Clinics in liver disease
Published: July 22, 2026
Letter: Therapeutic Targeting of PPARs in PBC-Additional Considerations. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: May 22, 2026
Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.
Journal: Alimentary pharmacology & therapeutics
Published: May 18, 2026
Improving the quality of paracentesis practices in people with advanced cirrhosis in an ambulatory care setting.
Journal: Journal of the Canadian Association of Gastroenterology
Published: April 30, 2026
Autoimmune hepatitis: special groups and treatment gaps.
Journal: JHEP reports : innovation in hepatology
Published: April 11, 2026
Meaningful Improvement Thresholds for Pruritus and Sleep Disturbance in PBC Using the Worst Itch and Sleep Interference Numerical Rating Scales.
Journal: Advances in therapy
Published: March 17, 2026
Can we cure primary biliary cholangitis?
Journal: Current opinion in immunology
Published: March 05, 2026
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.
Journal: Nature reviews. Gastroenterology & hepatology
Published: February 19, 2026
Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.
Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.
Journal: Hepatology communications
Published: February 16, 2026
Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat.
Journal: The lancet. Gastroenterology & hepatology
Published: December 19, 2025
Last Updated: 09/26/2026